同仁堂系全线暴涨 同仁堂集团拟开拓医药电商业务
格隆汇5月26日丨港A同仁堂系股票全线暴涨,同仁堂科技大涨11.21%,同仁堂科技旗下同仁堂国药涨12%;同仁堂国药母公司,A股上市的同仁堂(600085.SH)更是早早便涨停,现报41.47元。同仁堂科技与同仁堂股份、同仁堂商业及白兔信息,分别出资1250万、1250万、1300万和1200万元,成立合资公司,从事医药电商业务,而上述公司分别持有合营的25%、25%、26%及24%持股。同仁堂股份直接持有同仁堂科技46.85%股权,同仁堂股份则持有同仁堂商业51.98%股权。公告称,成立合资公司可整合同仁堂集团系统内部和外部资源,有助于实现资源的优化配置,逐步形成同仁堂医药电子商务产业一体化平台,扩大品牌影响力、拉动产品线上销售,满足该公司未来业务需求,并有助于进一步提升该公司业务的长期发展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.